IL319010A - NGF for the treatment of spasticity - Google Patents

NGF for the treatment of spasticity

Info

Publication number
IL319010A
IL319010A IL319010A IL31901025A IL319010A IL 319010 A IL319010 A IL 319010A IL 319010 A IL319010 A IL 319010A IL 31901025 A IL31901025 A IL 31901025A IL 319010 A IL319010 A IL 319010A
Authority
IL
Israel
Prior art keywords
spasticity
ngf
treatment
Prior art date
Application number
IL319010A
Other languages
English (en)
Hebrew (he)
Inventor
Marcello Allegretti
Andrea Aramini
Laura Brandolini
Franca Cattani
Flavio Mantelli
Original Assignee
Dompe Farm Spa
Marcello Allegretti
Andrea Aramini
Laura Brandolini
Franca Cattani
Flavio Mantelli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Farm Spa, Marcello Allegretti, Andrea Aramini, Laura Brandolini, Franca Cattani, Flavio Mantelli filed Critical Dompe Farm Spa
Publication of IL319010A publication Critical patent/IL319010A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
IL319010A 2022-09-23 2023-09-25 NGF for the treatment of spasticity IL319010A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22197562.6A EP4342485A1 (en) 2022-09-23 2022-09-23 Ngf for the treatment of spasticity
PCT/EP2023/076387 WO2024062135A1 (en) 2022-09-23 2023-09-25 Ngf for the treatment of spasticity

Publications (1)

Publication Number Publication Date
IL319010A true IL319010A (en) 2025-04-01

Family

ID=83438536

Family Applications (1)

Application Number Title Priority Date Filing Date
IL319010A IL319010A (en) 2022-09-23 2023-09-25 NGF for the treatment of spasticity

Country Status (7)

Country Link
EP (2) EP4342485A1 (https=)
JP (1) JP2025532676A (https=)
CN (1) CN120239610A (https=)
AU (1) AU2023345675A1 (https=)
CA (1) CA3266315A1 (https=)
IL (1) IL319010A (https=)
WO (1) WO2024062135A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026022244A1 (en) 2024-07-23 2026-01-29 Chiesi Farmaceutici S.P.A. A polypeptide for use in the therapeutic management of acute ischaemic stroke

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2213861T3 (es) 1998-10-09 2004-09-01 Scil Proteins Gmbh Procedimiento de obtencion de ngf-beta activa.
CN1112215C (zh) * 1999-12-28 2003-06-25 潘晓东 神经生长因子在治疗有机溶剂中毒性周围神经病中的用途
EP2907521B1 (en) 2011-12-19 2017-11-22 Wacker Chemie AG Novel prongf mutants and uses thereof in the production of beta-ngf
CN109153709B (zh) * 2016-03-18 2022-05-27 舒泰神（北京）生物制药股份有限公司 神经生长因子突变体
IT201600112420A1 (it) * 2016-11-08 2018-05-08 Univ Cattolica Del Sacro Cuore Nuova formulazione per via intranasale
US12378293B2 (en) 2018-04-27 2025-08-05 Chiesi Farmaceutici Spa Production of nerve growth factor (NGF) and of muteins thereof
PT4031117T (pt) * 2019-09-17 2024-10-25 Chiesi Farm Spa Mutante do ngf para utilização no tratamento ou prevenção de distúrbios oftálmicos
TW202229322A (zh) * 2020-11-19 2022-08-01 大陸商舒泰神（北京）生物製藥股份有限公司 長效神經生長因數多肽及其用途

Also Published As

Publication number Publication date
CA3266315A1 (en) 2024-03-28
EP4342485A1 (en) 2024-03-27
JP2025532676A (ja) 2025-10-01
WO2024062135A1 (en) 2024-03-28
CN120239610A (zh) 2025-07-01
AU2023345675A1 (en) 2025-03-06
EP4590324A1 (en) 2025-07-30

Similar Documents

Publication Publication Date Title
ZA202210745B (en) Method for the production of aav
GB202020573D0 (en) Novel methods of therapy
CA221425S (en) Therapy eye-mask
GB202020572D0 (en) Novel methods of therapy
IL319010A (en) NGF for the treatment of spasticity
SI3864053T1 (sl) Zdravljenje rms-ja z menjavo terapije
SG11202101819QA (en) Gene therapy for the treatment of galactosemia
IL287250A (en) treatment method
HUE067878T2 (hu) Eljárás alkilamidotiazolok gyártásához
IL306119A (en) Gene therapy for the treatment of beta-hemoglobinopathies
GB202003867D0 (en) Treatment of limbl spasticity
GB202206346D0 (en) Gene therapy
GB202011523D0 (en) Neuromodulation for the treatment of critical illness
GB202206348D0 (en) Treatment of limb spasticity
AU2022299062B2 (en) Environmental-friendly process for the treatment of wastewater
GB202003803D0 (en) Treatment of limb spasticity
AU2024396398A1 (en) Therapy for the treatment of multiple myeloma
GB202306826D0 (en) Therapy
GB202306833D0 (en) Therapy
GB202303026D0 (en) Therapy
GB202219335D0 (en) Therapy
GB202315695D0 (en) TReatment of cariomyopathy
GB202218595D0 (en) Therapy
GB202215997D0 (en) Therapy
GB202214514D0 (en) Therapy